Alan List, MD

Founder

Alan List, MD is a hematologist, medical oncologist and physician scientist who is internationally recognized for his many contributions in the development of effective treatment strategies for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He is currently the Chief Scientific Officer of Stelexis Biosciences. Previously, he served as the Chief Medical Officer of Precision Biosciences. He is the former President and CEO of Moffitt Cancer Center, past President of the Society of Hematologic Oncology and has authored more than 450 peer-reviewed manuscripts, chapters and books. His work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of MDS patients with chromosome 5q deletion. Dr. List was also a key leader in the development and FDA approval of two other agents for MDS, i.e., azacitidine (Vidaza®) and most recently, luspatercept (Reblozyl®). His laboratory investigations identified a previously unrecognized form of programmed cell death termed pyroptosis driving the pathobiology of MDS.

​​